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Abstract
Background: The polymerase chain reaction (PCR) and nucleic acid sequence-based amplification (NASBA) have been
recently modified by coupling to oligochromatography (OC) for easy and fast visualisation of products. In this study we
evaluate the sensitivity and specificity of the PCR-OC and NASBA-OC for diagnosis of Trypanosoma brucei gambiense and
Trypanosoma brucei rhodesiense human African trypanosomiasis (HAT).
Methodology and Results: Both tests were evaluated in a case-control design on 143 HAT patients and 187 endemic
controls from the Democratic Republic of Congo (DRC) and Uganda. The overall sensitivity of PCR-OC was 81.8% and the
specificity was 96.8%. The PCR-OC showed a sensitivity and specificity of 82.4% and 99.2% on the specimens from DRC and
81.3% and 92.3% on those from Uganda. NASBA-OC yielded an overall sensitivity of 90.2%, and a specificity of 98.9%. The
sensitivity and specificity of NASBA-OC on the specimens from DRC was 97.1% and 99.2%, respectively. On the specimens
from Uganda we observed a sensitivity of 84.0% and a specificity of 98.5%.
Conclusions/Significance: The tests showed good sensitivity and specificity for the T. b. gambiense HAT in DRC but rather a
low sensitivity for T. b. rhodesiense HAT in Uganda.
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Introduction
Human African trypanosomiasis (HAT) is an important public
health problem that affects rural populations of sub-Saharan
Africa. Previous estimates indicated an annual incidence of about
70,000 cases [1,2]. The number of cases in 2006 in the Democratic
Republic of the Congo (DRC) and Uganda was recently reported
to be 11382 and 486, respectively [3], but given the lack of
accurate reporting the actual number of cases is probably higher.
The disease in DRC is exclusively linked with Trypanosoma brucei
gambiense that causes the chronic form of HAT. Uganda represents
a unique case as it is the only country reporting both the chronic
and the acute form of HAT in hitherto non-overlapping foci. The
acute form is caused by T. b. rhodesiense and may claim the patients
in just a few weeks. Following infection, trypanosomes multiply
mainly in the lymph and/or blood (haemolymphatic stage). Over
time, the parasites cross the blood-brain barrier and invade the
central nervous system (neurological stage). HAT is almost
invariably fatal if left untreated and major efforts to control the
disease rely on vector and reservoir suppression (both human and
animal). For the latter, chemotherapy is the mainstay but
unfortunately relies on few drugs with unacceptable toxicity and
high relapse rates in some foci [4,5]. In addition to the search for
new trypanocidal compounds, current efforts to overcome the
problem of drug resistance involve rational use of existing drugs,
such as the recently reported nifurtimox-eflornithine combination
therapy (NECT) [6].
Control of HAT is challenged by unsatisfactory diagnostics,
although they play a central role in the decision to treat affected
individuals and in disease control. The card agglutination test for
trypanosomiasis (CATT) [7] is extensively used in screening for
Trypanosoma brucei gambiense although it may miss cases where the
infecting trypanosomes do not express the LiTat 1.3 variable
antigen type on which it is based [8,9]. For a similar reason, most
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date, a field applicable screening test for T. b. rhodesiense HAT has
remained elusive, despite attempts using procyclic trypanosomes
[10,11]. Hence, definite diagnosis is based on microscopic
demonstration of trypanosomes in the blood, lymph or cerebro-
spinal fluid. However, conventional microscopy exhibits a low
sensitivity and is therefore often combined with prior parasite
concentration such as the haematocrit centrifugation technique
(HCT) [12] and the miniature anion exchange centrifugation
technique (mAECT) [13]. Despite these innovations, up to 30% of
cases are still missed [14] leaving an undetected human reservoir.
Molecular methods for diagnosis of HAT are increasingly
gaining attention as possible ways to overcome the problem of low
sensitivity of the current parasite detection methods. Recently, two
innovative tests for T. brucei detection have been developed, the
PCR-Oligochromatography (OC) [15] and the NASBA-OC [16].
Both tests are based on nucleic acid amplification followed by
simple and rapid detection of the amplified products by dipstick.
While PCR-OC amplifies a short sequence within the 18S
ribosomal RNA (rRNA) gene by thermal cycling, NASBA-OC is
based on isothermal amplification of the 18S rRNA itself. Both
tests showed promising diagnostic accuracy during the phase I
evaluation studies [15,16] as well as satisfactory repeatability and
reproducibility in a multi center evaluation study (Mugasa et al.,
submitted). The aim of the presented study was to evaluate the




Participant recruitment and specimen collection was coordinat-
ed by the Institut National de la Recherche Biome ´dicale (INRB,
Kinshasa) in DRC and by Makerere University (Kampala) in
Uganda. Ethical clearance for the study was obtained from the
relevant institutional ethical committees in DRC (Ministry of
Health), Uganda (Ministry of Health) and Belgium (University of
Antwerp). Written consent was obtained from the study partici-
pants or their parents/guardians in presence of independent
witnesses.
Study participants
During this prospective study carried out between 2006 and
2008, T. brucei gambiense HAT patients were recruited from
Dipumba hospital in Mbuji-Mayi (Kasai-Oriental, DRC). Healthy
endemic control persons were recruited from the same region and
from volunteers at the University of Kinshasa (DRC). In Uganda,
T. b. rhodesiense HAT patients and healthy endemic control persons
were recruited at Namungalwe health centre (Iganga district,
Eastern Uganda) and Serere health centre (Soroti district,
Northeastern Uganda). Individuals were included in the study if
12 years old or more, not in critical condition and if the informed
consent was given. A patient was classified as HAT if parasites
were observed in the blood, lymph or cerebrospinal fluid (CSF).
Both patients in the early (haemolymphatic) and late (neurological)
stage were included. Individuals were classified as healthy endemic
controls if they had no history of HAT, no clinical signs suggestive
for HAT, were negative by CATT on whole blood and if no
trypanosomes were observed in the blood.
Reference tests
The CATT was executed on all participants in DRC and on the
endemic controls in Uganda [7]. When a positive CATT result on
whole blood was observed, the CATT was repeated with plasma
diluted 1/8 as described by Simarro and co-workers [17]. When
positive, the individual was subjected to parasitological detection
by direct examination of wet smears from lymph node aspirates,
Giemsa stained blood smears (only for T. b. rhodesiense), the HCT
[12] and/or mAECT [13]. Staging of the disease was done by
detecting parasites in the CSF by modified single centrifugation
[18] and/or by white blood cell (WBC) counting using the Fuchs-
Rosenthal chamber or disposable counting chambers (Uriglass,
Menarini). Patients with more than 5 cells per ml CSF and/or with
parasites in the CSF were considered late stage HAT.
Index tests
Specimen collection and transportation. Two hundred
microlitres of anti-coagulated blood was mixed with 200 mlo f
Angero NA buffer (Mallinckrodt Baker, USA) which allows
storage of the blood specimens without loss of nucleic acid
quality. Specimens were then transported in a cool-box containing
cooling elements from the collection sites to INRB in DRC or
Makerere University in Uganda. Upon arrival the specimens were
stored in a refridgerator at 4uC for a maximum of two weeks.
Isolation of nucleic acids. Nucleic acids of the blood
specimens were extracted at the INRB or Makerere University
using the method described by Boom et al. [19]. The nucleic acids
were eluted in 50 m1 of Tris-EDTA (TE) and centrifuged at 8000g
for 3 minutes where after 35 m1 of supernatant was stored at
280uC until further analysis.
PCR-OC and NASBA-OC. The nucleic acid extracts were
analysed with PCR-OC and NASBA-OC between July and
October 2008, as described by Deborggraeve et al. [15] and
Mugasa et al. [16] respectively. In brief, DNA or RNA is amplified
by PCR or NASBA where after the amplification products are
detected by dipstick. Dipstick test results were read after
10 minutes. Nucleic acids extracted from an in-vitro culture of
procyclic T. brucei gambiense (LiTat 1) were used as a positive
control. Ultrapure water and the nucleic acid extract of the blood
of a naı ¨ve volunteer from the Netherlands were used as negative
controls. A test was considered positive if a red line was visible at
the test line and if the control lines validated the test result [15,16].
Author Summary
Diagnosis plays a central role in the control of human
African trypanosomiasis (HAT) whose mainstay in disease
control is chemotherapy. However, accurate diagnosis is
hampered by the absence of sensitive techniques for
parasite detection. Without concentrating the blood,
detection thresholds can be as high as 10,000 trypano-
somes per milliliter of blood. The polymerase chain
reaction (PCR) and nucleic acid sequence-based amplifica-
tion (NASBA) are promising molecular diagnostics that
generally yield high sensitivity and could improve case
detection. Recently, these two tests were coupled to
oligochromatography (OC) for simplified and standardized
detection of amplified products, eliminating the need for
electrophoresis. In this study, we evaluated the diagnostic
accuracy of these two novel tests on blood specimens
from HAT patients and healthy endemic controls from D.R.
Congo and Uganda. Both tests exhibited good sensitivity
and specificity compared to the current diagnostic tests
and may be valuable tools for sensitive and specific
parasite detection in clinical specimens. These standard-
ized molecular test formats open avenues for improved
case detection, particularly in epidemiological studies and
in disease diagnosis at reference centres.
PCR and NASBA-OC for Human African Trypanosomiasis
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discrepancy, the result that was the same by two readers was taken
as consensus. The executors of the index tests were not blinded to
the participant classification and thus the results of the reference
tests.
Data collection and analysis
Data collection, analysis and reporting were done in consider-
ation of the ‘‘Strengthening the Reporting of Observational
Studies in Epidemiology’’ (STROBE) statement [20]. The
sensitivity and specificity of PCR- and NASBA-OC were
calculated from data entered into contingency tables. Sensitivity
was defined as the proportion of HAT cases that are positive by
the index test and specificity as the proportion of controls that are
negative by the index test. Differences in sensitivity and specificity
between the two tests were estimated by the Mc Nemar test and
differences among centers were estimated with the Fisher exact
test. Agreement between the two tests was determined using the
kappa index. A kappa index ranges from 0 to 1 and the higher the
value the stronger the agreement. All calculations were estimated
at a 95% confidence interval (95% CI).
Results
Participants
In the study 68 T. b. gambiense,7 5T. b. rhodesiense HAT patients
and 187 healthy endemic controls were recruited (table 1). Out of
the 68 T. b. gambiense cases, 17 showed parasites in the blood, 28 in
the lymph (of which 13 were blood negative), 60 in the CSF (of
which 34 were blood and lymph negative). Out of the 75 T. b.
rhodesiense cases, 73 showed parasites in the blood and 53 in the
CSF (of which 2 were blood negative). No lymph node aspirates
were examined in T. b. rhodesiense cases.
Sensitivity and specificity of PCR-OC and NASBA-OC
An overview of the sensitivity and specificities of both index tests
on the blood specimens of the participants recruited in the study is
presented in Table 2.
HAT patients
Trypanosomes were observed in the blood of 90 out of 143
stage I and II patients. The blood of 117 of the 143 was positive by
PCR-OC indicating a sensitivity of 81.8% (95% CI of 74.7–
87.3%), while we observed an overall sensitivity of 90.2% (95%CI:
84.2–94.1%) for NASBA-OC. Of the 187 healthy endemic
controls, 6 showed a positive PCR-OC result and 2 a positive
NASBA-OC result yielding an overall specificity of 96.8% (95%
CI: 93.2–98.5%) and 98.9% (95% CI: 96.2–99.7%), respectively.
While the difference in specificity of both tests was not significant,
the Mc Nemar test indicated a significant difference in sensitivity
(P,0.05).
T. brucei gambiense HAT
Out of the 68 patients from DRC, 56 were positive by PCR-OC
on blood indicating a sensitivity of 82.4% (95% CI: 71.6–89.6%).
Table 1. Human African Trypanosomiasis (HAT) patients and healthy endemic controls participating in the study.
Collection sites HAT patients Endemic controls
Total Stage I Stage II Parasitology Positive blood
D.R.Congo
Mbuji-Mayi 68 02 66 17 25
Kinshasa 00 00 00 00 97
Uganda
Namungalwe 25 03 22 25 29
Serere 50 07 43 48 36
doi:10.1371/journal.pntd.0000737.t001
Table 2. Sensitivities and specificities of the PCR-OC and NASBA-OC on the blood of HAT patients and healthy endemic controls
from D.R. Congo (DRC) and Uganda.
PCR-OC NASBA-OC










Overall 143 117 81.8 (74.7–87.3) 129 90.2 (84.2–94.1)
DRC 68 56 82.4 (71.6–89.6) 66 97.1 (90.0–99.2)
Uganda 75 61 81.3 (71.1–88.5) 63 84.0 (74.1–90.6)
Endemic controls
Overall 187 6 96.8 (93.2–98.5) 2 98.9 (96.2–99.0)
DRC 122 1 99.2 (95.5–99.9) 1 99.2 (95.6–99.9)
Uganda 65 5 92.3 (83.2–96.7) 1 98.5 (91.8–99.7)
Note. Nu=number; CI=confidence interval.
doi:10.1371/journal.pntd.0000737.t002
PCR and NASBA-OC for Human African Trypanosomiasis
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yielding a sensitivity of 97.1% (90.0–99.2%) which is significantly
higher than the sensitivity of PCR-OC (P,0.05). In only 17 of the
68 patients had parasites been observed in the blood by the
reference standard tests. Sixteen out of these 17 patients were
positive by PCR-OC (94%, 95% CI: 73%–99%) while all 17 were
positive in NASBA-OC (100%, 95% CI: 82%–100%). Of the 47
patients that were parasitologically negative in blood but positive
in lymph or CSF, 36 were positive by PCR-OC and 45 with
NASBA-OC. Four patients did not undergo microscopic exam-
ination of the blood (trypanosomes observed in other tissues) but
were all positive by PCR-OC and NASBA-OC.
T. brucei rhodesiense HAT
Of the 75 patients from Uganda, 73 had parasites in the blood
and 2 only in the CSF as determined by the reference tests. Sixty
one of the 75 patients were positive by PCR-OC (81.3% 95% CI:
71.1–88.5%) and 63 by NASBA-OC (84%, 95% CI: 74.1–90.6%),
which is not significantly higher (P.0.05). Of the 2 stage II
patients with negative parasite detection results in blood, 1 was
positive by PCR-OC and both by NASBA-OC.
Healthy endemic controls
One of the 122 endemic controls from DRC and 5 of the 65
endemic controls from Uganda were positive by PCR-OC. Hence,
the specificity of the test was 99.2% (95% CI: 95.5–99.9%) and
92.3% (95% CI: 83.2–96.7%), on the specimens from DRC and
Uganda respectively. The NASBA-OC was positive on 1 endemic
control from DRC and 1 from Uganda indicating a specificity of
99.2% (95% CI: 95.5–99.9%) and 98.5% (91.8–99.7%) for DRC
and Uganda respectively. These 2 endemic controls were also
positive in PCR-OC. There was no significant difference in
specificities between PCR-OC and NASBA-OC (P.0.05).
Test agreement and differences among centers
Considering all 330 specimens analysed in this study (143 cases
and 187 endemic controls), the two tests exhibited a kappa value of
0.85 (95% CI: 0.74–0.95). In DRC, the two tests showed a kappa
value of 0.88 (95% CI: 0.74–1.02) and in Uganda a kappa value of
0.8 (95% CI: 0.63–0.96). The Fisher exact test indicated a
significant difference (P,0.05) between the sensitivity of NASBA-
OC on specimens from DRC and from Uganda, and between the
specificities of the PCR-OC for the two countries. When we
compared results on the specimens collected in the two health
centers in Uganda, we observed no significant difference in the
specificity of both tests but a significant difference in sensitivity.
Discussion
This paper reports on the phase II evaluation of T. brucei PCR-
OC and NASBA-OC, two innovative molecular tests for the
diagnosis of HAT [15,16]. The PCR-OC showed a sensitivity of
82.4% on blood from 68 T. brucei gambiense HAT patients from
DRC, while the sensitivity on blood from 75 T. brucei rhodesiense
HAT patients from Uganda was 81.3%. The sensitivity of the test
on blood from the Congolese HAT patients is promising, since
most patients were in the neurological stage and parasites were
observed in the blood of only 17 patients by the reference tests.
One of these 17 patients showed a negative PCR-OC result
although parasites were detected in the blood by the HCT [12] on
2 capillaries. The detection threshold of the HCT and PCR-OC
were estimated at 500 trypanosomes [21] and 5 trypanosomes per
ml of blood [15] respectively. As conventional parasite detection is
usually highly specific, the negative PCR-OC test result might be
due to loss of DNA quality during specimen transport, storage or
nucleic acids extraction. Nevertheless, the observation that 36 out
of 47 patients whose blood was parasitologically negative were
positive by the PCR-OC indicates higher sensitivity of the test
compared to conventional parasite detection on blood. The 81.3%
sensitivity of the PCR-OC on the 75 T. brucei rhodesiense HAT
patients was unexpectedly low, given the fact that parasites were
observed in the blood of 73 of the 75 patients. Furthermore, T.
brucei rhodesiense infections are generally linked with acute HAT and
higher parasite load in patient blood. The hypothesis that the
PCR-OC is less sensitive on T. brucei rhodesiense than on T. brucei
gambiense is unlikely since we expect the DNA target copy numbers
in the two subspecies to be in the same range. The observed low
sensitivity on the HAT cases from Uganda could have been loss of
DNA or DNA quality due to unsuccessful sample storage or DNA
extraction. These samples were collected over a period of two
years, nucleic acids being extracted and frozen as they were
delivered from the rural treatment centers to the central
laboratories. DNA quality could have been checked by amplifying
a part of the human ß-globin gene [22] but this could be biased by
the much higher number of human cells in the specimen. Batch to
batch variation of the PCR-OC is implausible since extensive
quality control was performed on the test kits prior to dispatch to
trial centers. This highlights a weak point of our study, namely the
lack of external quality control on a subset of specimens at a
central reference laboratory. In addition, test executors were not
blinded to the participant classification and we did not apply
subspecies-specific PCRs to confirm the presence of T. b. gambiense
and T. b. rhodesiense in the clinical specimens of the HAT cases.
Although the HAT patients in Uganda were recruited in T. b.
rhodesiense areas, infection with T. b. gambiense can not be fully
excluded since both subspecies are present in this country.
Another limitation of the study was that each specimen was tested
only once with each index test. However, both assays have proven
to be repeatable and reproducible in a multicentre evaluation
study comprising 9 different laboratories (Mugasa et al. submitted).
The PCR-OC was positive for one of the 122 endemic controls
from DRC and 5 of the 66 endemic controls from Uganda. These
might be true HAT cases since the sensitivity of the CATT is not
100%; confirmed T. brucei gambiense HAT patients with negative
CATT have been reported [8,9,23], while an accurate serological
test for T. b. rhodesiense HAT remains elusive. However, neither
DNA contamination during nucleic acid extraction or PCR, nor
cross-reaction of the test with DNA from other organisms can be
excluded, although such cross-reactions were not observed during
the phase I evaluation [15].
The observed higher sensitivity of the NASBA-OC is not
unexpected, given that this assay targets the 18S ribosomal RNA
(rRNA) while the PCR-OC targets the 18S rRNA gene. It has
been documented that the 18S rRNA is present in approximately
10,000 copies, at least 100 times more that the 18S rRNA gene
copy number [24]. Indeed, in a study to compare quantitative
assays, van der Meide et al. [25] observed that the RNA amplifying
assays such as NASBA and real time reverse transcriptase PCR
detect lower parasite loads compared to real-time PCR. However,
in line with the PCR-OC results, the sensitivity of the NASBA-OC
on the T. b. rhodesiense HAT specimens is surprisingly low and
significantly lower than the sensitivity on the T. b. gambiense HAT
specimens. Given the general high parasite load in the blood of T.
b. rhodesiense HAT patients, defects in specimen processing, storage
and/or transportation are more likely to have contributed to the
observed sensitivity than a lower diagnostic performance of the
assay for T. b. rhodesiense. Although comparisons between foci
should be critically made since specimen collection and DNA
PCR and NASBA-OC for Human African Trypanosomiasis
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laboratories, further evaluation studies may clarify the observed
discrepancy in sensitivity on both subspecies. The NASBA-OC
showed a higher specificity on the endemic controls compared to
PCR-OC. This might indicate that DNA contamination during
specimen processing is more likely the cause of the low specificity
of PCR-OC than the presence of true HAT cases among the
endemic controls.
Recently, Lutumba and colleagues estimated the effectiveness of
the best current diagnostic algorithm for T .b. gambiense HAT at
80% (quantified in terms of the number of lives saved) [26].
Hence, the observed sensitivities of PCR-OC and NASBA-OC are
probably higher than each of the current parasite detection tests
used alone and could improve this effectiveness. However, one
should bear in mind that the PCR-OC and NASBA-OC are not
yet an option for routine diagnosis at the primary care level as they
require basic molecular biology laboratory facilities [27]. HAT
typically affects rural populations in sub-Saharan Africa where
health centers most often suffer from infrastructural limitations
and thus only apply less sophisticated diagnostic methods. Yet,
these standardized molecular test formats can be valuable tools in
disease surveillance and epidemiological studies in which speci-
mens are analysed at central reference laboratories. In recent
years, the loop-mediated isothermal amplification (LAMP) has
emerged as another isothermal amplification technique for the
detection of T. brucei nucleic acids [28,29]. The LAMP, being
isothermal, is similar to NASBA but amplifies DNA instead of
RNA and might thus be less prone to effects of specimen
degradation during transport and storage. Although the diagnostic
accuracy of LAMP on clinical specimens still has to be proven, the
technique is promising and comparative evaluation of NASBA and
LAMP on the same patients and controls would be useful. In this
study, we could not evaluate the PCR-OC and NASBA-OC for
disease staging as CSF specimens were not included in the analysis
with the index tests. Hence, further evaluations of the tests for
disease diagnosis and staging are required.
In conclusion, the sensitivity and specificity of the PCR-OC and
NASBA-OC were successfully evaluated in a case-control study in
DRC and Uganda. The tests showed good sensitivity and
specificity for T. b. gambiense HAT but a rather low sensitivity for
T. b. rhodesiense HAT in Uganda.
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